Ingrid Zhang, president of Novartis Pharmaceuticals China, shares the transformation of Novartis China in the past two years in line with the global Novartis vision; their aspiration to become a powerhouse for bringing innovative products to China and to develop talents; their commitment to working with various stakeholders to promote better patient outcomes; her aspirations for flagship products ENTRESTO® and COSENTYX®; and her mission to develop Novartis China further as one of the most respected and ‘unbossed’ companies in China.
Novartis has been present in China for the last three decades, during which we launched about 62 medicines (including different indications)
